539 related articles for article (PubMed ID: 31145586)
1. Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease.
Shi Y; Lu X; Zhang L; Shu H; Gu L; Wang Z; Gao L; Zhu J; Zhang H; Zhou D; Zhang Z
ACS Chem Neurosci; 2019 Aug; 10(8):3479-3485. PubMed ID: 31145586
[TBL] [Abstract][Full Text] [Related]
2. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
3. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
[TBL] [Abstract][Full Text] [Related]
4. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.
Dark HE; An Y; Duggan MR; Joynes C; Davatzikos C; Erus G; Lewis A; Moghekar AR; Resnick SM; Walker KA
Alzheimers Res Ther; 2024 Apr; 16(1):94. PubMed ID: 38689358
[TBL] [Abstract][Full Text] [Related]
6. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
Bolsewig K; van Unnik AAJM; Blujdea ER; Gonzalez MC; Ashton NJ; Aarsland D; Zetterberg H; Padovani A; Bonanni L; Mollenhauer B; Schade S; Vandenberghe R; Poesen K; Kramberger MG; Paquet C; Bousiges O; Cretin B; Willemse EAJ; Teunissen CE; Lemstra AW;
Neurology; 2024 Jun; 102(12):e209418. PubMed ID: 38830138
[TBL] [Abstract][Full Text] [Related]
7. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease.
Pereira JB; Westman E; Hansson O;
Neurobiol Aging; 2017 Oct; 58():14-29. PubMed ID: 28692877
[TBL] [Abstract][Full Text] [Related]
8. Future perspective and clinical applicability of the combined use of plasma phosphorylated tau 181 and neurofilament light chain in Subjective Cognitive Decline and Mild Cognitive Impairment.
Giacomucci G; Mazzeo S; Ingannato A; Crucitti C; Bagnoli S; Padiglioni S; Romano L; Galdo G; Emiliani F; Frigerio D; Ferrari C; Moschini V; Morinelli C; Notarelli A; Sorbi S; Nacmias B; Bessi V
Sci Rep; 2024 May; 14(1):11307. PubMed ID: 38760423
[TBL] [Abstract][Full Text] [Related]
9. Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid.
Jia L; Qiu Q; Zhang H; Chu L; Du Y; Zhang J; Zhou C; Liang F; Shi S; Wang S; Qin W; Wang Q; Li F; Wang Q; Li Y; Shen L; Wei Y; Jia J
Alzheimers Dement; 2019 Aug; 15(8):1071-1080. PubMed ID: 31422798
[TBL] [Abstract][Full Text] [Related]
10. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
[TBL] [Abstract][Full Text] [Related]
11. Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients.
Mendes AJ; Ribaldi F; Lathuiliere A; Ashton NJ; Zetterberg H; Abramowicz M; Scheffler M; Assal F; Garibotto V; Blennow K; Frisoni GB
Alzheimers Res Ther; 2024 May; 16(1):110. PubMed ID: 38755703
[TBL] [Abstract][Full Text] [Related]
12. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition.
Rauchmann BS; Schneider-Axmann T; Perneczky R;
J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1289-1295. PubMed ID: 34187867
[TBL] [Abstract][Full Text] [Related]
13. Serum Markers of Neurodegeneration Are Strongly Linked to Heart Failure Severity and Outcome.
Wurm R; Prausmüller S; Ponleitner M; Spinka G; Weidenhammer A; Arfsten H; Heitzinger G; Panagiotides NG; Strunk G; Bartko P; Goliasch G; Stögmann E; Hengstenberg C; Hülsmann M; Pavo N
JACC Heart Fail; 2024 Jun; 12(6):1073-1085. PubMed ID: 38839151
[TBL] [Abstract][Full Text] [Related]
14. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.
Startin CM; Ashton NJ; Hamburg S; Hithersay R; Wiseman FK; Mok KY; Hardy J; Lleó A; Lovestone S; Parnetti L; Zetterberg H; Hye A; ; Strydom A
Alzheimers Res Ther; 2019 Mar; 11(1):26. PubMed ID: 30902060
[TBL] [Abstract][Full Text] [Related]
15. Correlation Between Brain Structure Atrophy and Plasma Amyloid-β and Phosphorylated Tau in Patients With Alzheimer's Disease and Amnestic Mild Cognitive Impairment Explored by Surface-Based Morphometry.
Li K; Qu H; Ma M; Xia C; Cai M; Han F; Zhang Q; Gu X; Ma Q
Front Aging Neurosci; 2022; 14():816043. PubMed ID: 35547625
[TBL] [Abstract][Full Text] [Related]
16. Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study.
Albani D; Marizzoni M; Ferrari C; Fusco F; Boeri L; Raimondi I; Jovicich J; Babiloni C; Soricelli A; Lizio R; Galluzzi S; Cavaliere L; Didic M; Schönknecht P; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Bocchio L; Salvatore M; Rossini PM; Tsolaki M; Visser PJ; Richardson JC; Wiltfang J; Bordet R; Blin O; Forloni G; Frisoni GB;
J Alzheimers Dis; 2019; 69(1):37-48. PubMed ID: 30149449
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.
Honig LS; Kang MS; Lee AJ; Reyes-Dumeyer D; Piriz A; Soriano B; Franco Y; Coronado ZD; Recio P; Mejía DR; Medrano M; Lantigua RA; Teich AF; Dage JL; Mayeux R
JAMA Netw Open; 2023 Apr; 6(4):e238214. PubMed ID: 37079306
[TBL] [Abstract][Full Text] [Related]
18. Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease.
Chatterjee P; Zetterberg H; Goozee K; Lim CK; Jacobs KR; Ashton NJ; Hye A; Pedrini S; Sohrabi HR; Shah T; Asih PR; Dave P; Shen K; Taddei K; Lovejoy DB; Guillemin GJ; Blennow K; Martins RN
J Neuroinflammation; 2019 Oct; 16(1):186. PubMed ID: 31601232
[TBL] [Abstract][Full Text] [Related]
19. Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease.
Illán-Gala I; Lleo A; Karydas A; Staffaroni AM; Zetterberg H; Sivasankaran R; Grinberg LT; Spina S; Kramer JH; Ramos EM; Coppola G; La Joie R; Rabinovici GD; Perry DC; Gorno-Tempini ML; Seeley WW; Miller BL; Rosen HJ; Blennow K; Boxer AL; Rojas JC
Neurology; 2021 Feb; 96(5):e671-e683. PubMed ID: 33199433
[TBL] [Abstract][Full Text] [Related]
20. Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology.
Liu HC; Lin WC; Chiu MJ; Lu CH; Lin CY; Yang SY
PLoS One; 2020; 15(6):e0234519. PubMed ID: 32530970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
